rAAV Capsid VR1 Loop Modifications for Muscle Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated virus (rAAV) vectors, particularly rAAV1, suffer from sub-therapeutic levels of transgene expression in muscle tissue despite high doses, limiting their effectiveness in treating conditions like α-1 antitrypsin deficiency and muscular dystrophy.
Innovation Solution
Modified capsid proteins with specific amino acid deletions or substitutions in the variable region 1 (VR1) loop of rAAV capsids, disrupting hydrogen bonding patterns to enhance transduction efficiency, resulting in up to 12.5-fold increased transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of rAAV1 are administered intramuscularly, then serum levels of therapeutic protein increase, but transgene expression remains sub-therapeutic
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the rAAV1 capsid protein, specifically altering residues in the variable region 1 (VR1) loop. These sequence parameter changes result in capsid proteins with enhanced transduction efficiency, achieving up to 12.5-fold increase in transgene expression in muscle tissue compared to wild-type rAAV1, thereby resolving the contradiction between dosage quantity and transduction efficiency.
2Quantity of substance
If multiple intramuscular injections are administered to achieve therapeutic expression, then serum protein levels increase, but the procedure becomes impractical
Solution Approach 1:
By changing the amino acid parameters of the capsid protein (specifically VR1 loop residues), the patent creates modified rAAV1 vectors that achieve therapeutic transgene expression with fewer injections. The enhanced transduction efficiency of the modified capsid reduces the number of intramuscular injections required from multiple high-dose administrations to a practical treatment regimen, resolving the operational feasibility issue.
3Productivity
If the capsid structure is modified to enhance transduction, then transgene delivery efficiency improves, but the capsid stability may be compromised
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions specifically in the variable region 1 (VR1) loop of the capsid protein, rather than modifying the entire capsid structure. This localized modification approach allows enhancement of transduction efficiency through changes in receptor interaction properties while preserving the overall structural stability and integrity of the capsid, resolving the contradiction between transduction efficiency and structural stability.
Data Source
AI summary
This invention relates to modified parvovirus capsid proteins with enhanced transduction efficiency, viral vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell or a subject.